Prucalopride for Cognitive Functioning in Schizophrenia

NANot yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Schizophrenia
Interventions
DRUG

Prucalopride 1 MG

The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.

Trial Locations (1)

575018

K S Hegde Medical Academy,, Mangalore

All Listed Sponsors
collaborator

Fogarty International Center of the National Institute of Health

NIH

collaborator

K S Hegde Medical Academy

UNKNOWN

lead

University of Pittsburgh

OTHER

NCT06474286 - Prucalopride for Cognitive Functioning in Schizophrenia | Biotech Hunter | Biotech Hunter